Abliva

Financing enables start of the registrational FALCON study with KL1333
NV354 data is being assembled for a clinical trial application

Important events first quarter (Jan - Mar 2022)

• An extraordinary general meeting was held on 14 January 2022. The general meeting approved the Board of Directors’ resolution from 20 December 2021 on a directed issue of convertible bonds amounting to SEK 26 million.

Important events after the reporting period

• On May 31, Abliva’s Board of Directors announced funding of approximately SEK 200 million that will provide the company with the capital required to pursue the Phase 2/3 study with KL1333 to a key interim analysis, as well as prepare NV354 for clinical phase. For more information see pages 10-11.
• Annual General Meeting was held on May 20, 2022.

Financial information

January-March 2022*

• Net revenues: SEK 0,000 (0,000)
• Other operating income: SEK 0,000 (0,000)
• Loss before tax: SEK 22,028,000 (21,456,000)
• Loss per share before dilution: SEK 0.05 (0.07)
• Diluted loss per share: SEK 0.05 (0.07)

* APM Alternative perfomance measures, see definition on page 20.

The complete Interim report is available for download below and through Abliva's website www.abliva.com